Skip to main content

Table 2 Univariate and Multivariable survival analyses of the subgroup of untreated patients, N = 102*

From: Tumor tissue levels of Tissue Inhibitor of Metalloproteinases-1 (TIMP-1) and outcome following adjuvant chemotherapy in premenopausal lymph node-positive breast cancer patients: A retrospective study

Univariate DFS   OS  
   HR (95% CI) P HR (95% CI) P
TIMP-1 Continuous variable 0.96 (0.63-1.45) 0.84 0.72 (0.39-1.33) 0.29
  High vs. low 0.93 (0.58-1.49) 0.76 0.72 (0.39-1.33) 0.3
Multivariable DFS   OS  
   HR (95% CI) P HR (95% CI) P
TIMP-1 Continuous variable 0.95 (0.60-1.51) 0.84 0.80 (0.41-1.57) 0.52
  High vs. low 0.95 (0.56-1.62) 0.86 0.80 (0.41-1.54) 0.5
Age 41-55 years vs. ≤ 40 years 0.53 (0.31-0.89) 0.02 0.40 (0.21-0.77) 0.01
Tumor size Stage 2 (> 2 cm) vs. stage 1 (≤ 2 cm) 1.76 (0.93-3.33) 0.19 1.77 (0.72-4.36) 0.37
  Stage 3 (>5 cm or chest wall/skin involvement) vs. stage 1 (≤ 2 cm) 1.35 (0.58-3.14)   2.01 (0.62-6.45)  
Grade Unknown vs. poor 0.70 (0.40-1.22) 0.39 0.83 (0.41-1.67) 0.51
  Well/moderate vs. poor 0.74 (0.33-1.64)   0.54 (0.18-1.64)  
  1. * Analyses stratified for hormone receptor status, nodal status and RT on the axilla. The results for age, tumor size and grade are from the base model not including TIMP-1. TIMP-1 was added separately as a continuous variable and then as a dichotomized one. The coefficients for age, tumor size and grade are similar with TIMP-1 included.